Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+/HER2- breast cancer: A case report

This case report followed a 58-year-old post-menopausal Middle Eastern woman with stage IV HR+ HER2- breast cancer with extensive bone metastases. After treatment regimen failure and disease advancement following letrozole and zoledronic acid in conjunction with adjuvant radiotherapy, the patient began a regimen of palbociclib and fulvestrant. This combination led to stable disease after 3 months, which has continued for approximately 3 years, up to the point of reporting.